BICX: New Grant, Patent Filed

By Beth Senko, CFA

OTC:BICX

READ THE FULL BICX RESEARCH REPORT

BioCorRx, Inc. (OTC:BICX) is at an early point in front of a vast market opportunity for medication assisted treatment (MAT) of opioid and alcohol use disorders. In September, the Company received a $3.5 million grant to support further development and clinical trials of its subcutaneous pellet of naltrexone (BICX104). Trials are expected to commence later this year. While it may be 2024-25 to see significant revenues from its BICX104 development efforts, we believe that the Company is on the right long-term path for sustainable growth.

Since receiving US FDA IND approval for its subcutaneous naltrexone pellet, BICX104, for the treatment of opioid and alcohol use disorders, in May 2021, BioCorRx continues to move forward towards initiating clinical trials before the end of this year. September was particularly newsworthy, with BioCorRx receiving a new grant, filing a US patent and expanding its manufacturing arrangement.

BioCorRx, Inc. develops and markets medication-assisted treatment and behavioral therapy programs to treat opioid use disorder (OUD), alcohol use disorder (AUD), and weight-management. The Company’s offerings combine proprietary cognitive-behavioral-therapy (CBT) and peer support with medications (primarily naltrexone) prescribed by a physician which can enable them to provide customizable solutions to their patients. BioCorRx has sold its Beat Addiction Recovery program for OUD and AUD since 2010.

On September 1, BioCorRx received a $3.5 million grant from the National Institute on Drug Abuse (NIDA) to help fund its first clinical trial for BICX104. The new funding is in addition to two grants of $2.8 million each received in 2019 and 2020. On September 22, BioCorRx announced it filed a patent application with the U.S. Patent and Trademark Office (USPTO) for a biodegradable implant including naltrexone.

BioCorRx is seeking approval for its subcutaneous naltrexone pellet (BICX104) for the treatment of opioid use (OUD) and alcohol use (AUD) disorders under the US FDA 505(b)(2) pathway. The upcoming clinical trial focuses on local safety and pharmacokinetics of BICX104. The phase 1, six-month open label trial will enroll 24 healthy volunteers. (A Randomized, Open Label, Single Dose Pharmacokinetic and Safety Study of Implantable Long Acting 3-month Naltrexone Subcutaneous Pellets Compared to Naltrexone IM Injection (Vivitrol) in Healthy Volunteers). Patients in the experimental arm will receive a single BICX104, subcutaneous naltrexone implant and monitored for 84 days. Patients in the active comparator arm will receive Vivitrol intramuscular injection containing 380 mg of naltrexone. Three consecutive doses will be administered once every 28 days for 84 days.

The trial will compare patients in both arms on pharmacokinetic parameters (drug and plasma levels of naltrexone over time) and safety (primarily incidence and severity of adverse events related to implantation).

On September 8, BioCorRx expanded its agreement with Recro Pharma (REPH – NASDAQ), to manufacture and validate batches of BICX104 for use in the clinical trials and approval process. The next step is to sign a clinical research organization (CRO) to oversee the trial. Management expects to complete that decision soon. Along with BioCorRx, Recro and the CRO will establish timelines for starting the trial. If all goes according to plan, the goal is to dose the first patient before the end of 2021 and submit its NDA application for approval in 2022.

BioCorRx will devote the next few years to seeking approval for BICX104, working to gain payer reimbursement for its addiction treatment program and building out sales of UnCraveRx, for weight management. During the next two years, we expect catalysts to come from several areas:

• Clinical milestones for BICX104 and progress towards filing for FDA approval.

• Public health and policymaker actions to educate the public and providers on the benefits of MAT.

• Expanded access to MAT in office-based settings.

• Fewer hurdles to insurance reimbursement for MAT in both private and public payer programs.

Our intrinsic value for BICX of $5.65/share is based on an NPV for an FDA-approved naltrexone implant for OUD and AUD, the Company’s addiction recovery program, and the UnCraveRx program for weight management. Our model assumes BICX carries all R&D costs through approval (estimated range of $12-15 million) partially offset by research grants of nearly $10 million through 2023.

Several factors provide upside to our valuation including: additional research funding beyond our $10 million assumption, partnership that provides milestones and/or R&D cost sharing; a faster, or less-costly path to US approval; and the potential for sales in other geographies and indications as well as the possibility of additional approvals.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. 

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer HERE.

COMMENTS

WORDPRESS: 0
DISQUS: 0